文献速递骨肿瘤关节外科

骨肉瘤膝关节假体置换术后如何区分局部复发与异位骨化

How Can We Differentiate Local Recurrence From Heterotopic Ossification After Resection and Implantation of an Oncologic Knee Prosthesis in Patients with a Bone Sarcoma?
PubMed 文献 · Clin Orthop Relat Res · 2021-01-01

本研究回顾性分析278例骨肉瘤膝关节假体重建患者,异位骨化(HO)发生率为8%,局部复发(LR)为10%。2年无HO生存率与无LR生存率无差异。感染史、男性、特定假体类型与HO相关;边界不清、疼痛、较晚出现提示LR。

要点

  • 术后异位骨化与局部复发在2年生存率上无显著差异。
  • 感染史、男性、使用Modular Universal Tumor and Revision System假体与HO发生相关。
  • 边界不清、疼痛、出现时间较晚更提示局部复发而非异位骨化。

核心结论

  • 骨肉瘤膝关节假体重建术后异位骨化可发生,多数可通过影像学边界清晰与否与局部复发鉴别。
  • 出现时间早且无疼痛提示异位骨化,而边界不清、疼痛、出现较晚提示局部复发。

研究设计与样本

  • 回顾性研究,纳入2002至2018年409例原发骨肿瘤切除后膝关节肿瘤假体重建患者,最终278例纳入分析。
  • 由两名观察者分析术后平均63±33个月的正侧位X线片,定义异位骨化为软组织内骨形成。
  • 采用竞争风险估计法计算无HO生存率,单因素分析比较HO与无病变及HO与LR的特征。

主要发现

  • 278例中HO发生率为8%(21/278),LR发生率为10%(28/278)。
  • 2年无HO生存率为76±5%(95%CI 63-87),无LR生存率为74±5%(95%CI 62-88),两者无差异(p=0.19)。
  • HO组感染史比例19%(4/21)高于无病变组5%(12/229),OR 6(95%CI 2-17),p<0.001。
  • HO组男性比例76%(16/21)高于无病变组55%(128/229),OR 2(95%CI 1-5),p=0.03。
  • HO组使用Modular Universal Tumor and Revision System假体比例67%(14/21)高于无病变组40%(92/229),OR 2(95%CI 1-5),p=0.02。

关键数值与推荐

  • 影像学病变边界不清在HO组为19%(4/21),在LR组为100%(28/28),OR 8(95%CI 3-20),p<0.001。
  • HO出现的中位时间8个月(范围3-13)短于LR的16个月(范围11-21),95%CI 10-13,p<0.001。
  • LR组就诊时疼痛比例86%(24/28)高于HO组14%(3/21),OR 36(95%CI 7-181),p<0.001。

临床怎么用

  • 术后影像发现软组织骨化时,边界清晰者多提示异位骨化,边界不清需警惕局部复发。
  • 出现时间早且无疼痛的骨化病变更符合异位骨化,出现较晚伴疼痛者应进一步排查复发。
  • 有感染史、男性或使用特定假体的患者应加强异位骨化的影像监测与鉴别。

局限性

  • 本研究为单中心回顾性研究,证据等级为Level III。
  • 部分患者因死亡、失访、影像缺失或合并其他情况被排除,最终仅278例纳入分析。
  • 统计方法采用单因素分析,未进行多因素校正。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Heterotopic ossification (HO) is common after total joint arthroplasty and usually does not cause diagnostic problems. However, the occurrence of HO after oncologic prostheses implantation can be troublesome as it may mimic a locally recurrent tumor. Because this distinction could have a profound impact on the surgeon and patient, it is important to distinguish the two entities; to our knowledge, no study has evaluated this after oncologic endoprosthetic reconstruction around the knee after tumor resection. QUESTIONS/PURPOSES: (1) How common is the occurrence of HO compared with local recurrence (LR) after resection of bone sarcoma and the use of an oncologic knee prosthesis? (2) Are there any factors associated with the development of HO after limb salvage procedures with an endoprosthesis? (3) What features allow the surgeon to differentiate HO from a locally recurrent tumor in this setting? METHODS: Between 2002 and 2018, we performed 409 resections of primary bone tumors followed by reconstructions with oncologic endoprostheses. Of these, 17% (71 of 409) died before 2 years and did not have HO at that time, 2% (8 of 409) were lost to follow-up before 2 years, and another 2% (10 of 409) did not have radiographs available at a minimum of 2 years after surgery (and had not developed HO before then), and so could not be analyzed, leaving 320 patients for analysis in this retrospective study. Forty-two patients were excluded; 2% (5 of 320) for a history of failed allograft reconstruction, 3% (8 of 320) for pathologic fracture at presentation, 2% (6 of 320) for inadequate or complicated biopsy, 1% (2 of 320) for stem fractures, 2% (7 of 320) for stem loosening, and 4% (14 of 320) for extracortical bone bridging, leaving 278 patients for final evaluation. Two observers analyzed AP and lateral radiographs for signs of HO at a mean follow-up of 63 ± 33 months after surgery. We defined HO as extraskeletal bone formation in soft tissues. The primary study endpoint was survivorship free from HO, as ascertained by a competing-risks estimator. To identify factors associated with HO appearance, the demographic, radiographic, clinical, pathologic, and surgical characteristics were compared between patients with HO and those who had no lesion. Characteristic features were also compared between patients with HO and those with LR to help their differentiation. Univariate analysis was used for all statistical evaluations. RESULTS: HO developed in 8% (21 of 278) of patients in whom oncologic knee prosthesis was implanted. LR developed in 10% (28 of 278) of the patients. According to survivorship estimates, the HO-free survival rate was not different from the LR-free survival rate at 2 years after oncologic knee reconstruction (76 ± 5% [95% CI 63 to 87] versus 74 ± 5% [95% CI 62 to 88]; p = 0.19). History of infection was more common in patients with HO than in patients with no lesion (19% [4 of 21] versus 5% [12 of 229], Odds ratio [OR] 6 [95% CI 2 to 17]; p < 0.001). The male sex was more common in the HO group as well (76% [16 of 21] versus 55% [128 of 229], OR 2 [95% CI 1 to 5]; p = 0.03). The Modular Universal Tumor and Revision System prosthesis was more frequently used in patients with HO (67% [14 of 21]) compared to those with no lesions (40% [92 of 229]; OR 2 [95% CI 1 to 5]; p = 0.02). The lesion border in radiographs was ill-defined in 19% (4 of 21) of patients with HO and 100% (28 of 28) of patients with LR (OR 8 [95% CI 3 to 20]; p < 0.001). The median time to the appearance of HO was shorter than the time to LR (8 months [3 to 13] versus 16 months [11 to 21], [95% CI 10 to 13]; p < 0.001). Pain at presentation was more frequent in patients with LR than in those with HO (86% [24 of 28] versus 14% [3 of 21], OR 36 [95% CI 7 to 181]; p < 0.001). CONCLUSION: HO may occur after the use of oncologic knee prostheses for reconstruction after tumor resection. In most patients, HO could be differentiated from local recurrence through identifying a well-defined border on radiographs. Otherwise, factors such as an earlier time of presentation and absence of pain could suggest an HO, rather than an LR. LEVEL OF EVIDENCE: Level III, therapeutic study.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. Jamshidi K, Bagherifard A, Al-Baseesee HH, et al. How Can We Differentiate Local Recurrence From Heterotopic Ossification After Resection and Implantation of an Oncologic Knee Prosthesis in Patients with a Bone Sarcoma? Clin Orthop Relat Res. 2021. PMID: 33861216. doi:10.1097/CORR.0000000000001539

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。